| Literature DB >> 24142821 |
Robert J Morgan1, Ronald D Alvarez, Deborah K Armstrong, Robert A Burger, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David M Gershenson, Heidi J Gray, Ardeshir Hakam, Laura J Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A Matulonis, David M O'Malley, Richard T Penson, Matthew A Powell, Steven W Remmenga, Paul Sabbatini, Joseph T Santoso, Julian C Schink, Nelson Teng, Theresa L Werner, Mary A Dwyer, Miranda Hughes.
Abstract
These NCCN Guidelines Insights focus on the major updates to the 2013 NCCN Guidelines for Ovarian Cancer. Four updates were selected based on recent important updates in the guidelines and on debate among panel members about recent clinical trials. The topics include 1) intraperitoneal chemotherapy, 2) CA-125 monitoring for ovarian cancer recurrence, 3) surveillance recommendations for less common ovarian histopathologies, and 4) recent changes in therapy for recurrent epithelial ovarian cancer. These NCCN Guidelines Insights also discuss why some recommendations were not made.Entities:
Mesh：
Year: 2013 PMID： 24142821 DOI： 10.6004/jnccn.2013.0142
Source DB: PubMed Journal: J Natl Compr Canc Netw ISSN： 1540-1405 Impact factor: 11.908